Rxsight Inc (RXST) Stock Analysis

AI analysis of Rxsight Inc (RXST)

Hold

RxSight Inc is not a strong buy at the moment due to its current price of $4.80 being significantly below its 52-week high of $13.22 and the forward P/E ratio of 116.28 indicating high valuation concerns. The company is facing challenges with a net loss of $12.1 million reported for Q2 2026, which reflects ongoing financial difficulties. While the gross margin remains relatively strong at 76.72%, the withdrawal of full-year guidance and a projected EPS loss of $0.42 for the next earnings report suggest caution. The main risk is the high forward P/E ratio, which indicates that the stock may be overvalued given its current financial performance.

Valuation Metrics

The current forward P/E ratio for Rxsight Inc (RXST) is 116.28, compared to its 5-year average forward P/E of -1.74.

Forward P/E

Overvalued

5Y Average P/E

-1.74

Current P/E

116.28

Overvalued

64.20

Undervalued

-67.68

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

-23.64

Current EV/EBITDA

-3.28

Overvalued

5.29

Undervalued

-52.56

Forward P/S

Undervalued

5Y Average P/S

6.83

Current P/S

1.28

Overvalued

10.78

Undervalued

2.89

Alphio AI Price Scenarios for RXST

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%RXST

$29.72

Scenario price

B

Base

Base · 50%RXST

$25.46

Scenario price

B

Bear

Bear · 25%RXST

$19.14

Scenario price

Whales holding RXST

N

No Street GP LP

+ HoldingRXST

-3.80%

3M Return

RXST FAQ — answered by Alphio AI

RxSight, Inc. is a commercial-stage medical technology company engaged in providing customized vision to patients following cataract surgery. Its RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system is composed of RxSight Light Adjustable Lens (LAL), RxSight Light Delivery Device (LDD) and related accessories. The LAL is an intraocular lens (IOL) made from the silicone-based photosensitive material that undergoes controlled changes in refractive power when exposed to specific ultraviolet (UV) light patterns generated by the LDD. Its LAL uses a silicone formulation that enables changing the mechanical and optical properties of the lens following implantation. The LDD uses software and algorithms to deliver a short UV light exposure treatment that polymerizes specific portions of the lens and allows doctors to adjust spherical and cylindrical refraction. It operates in the Healthcare sector (OPHTHALMIC GOODS industry).

RxSight Inc is not a strong buy at the moment due to its current price of $4.80 being significantly below its 52-week high of $13.22 and the forward P/E ratio of 116.28 indicating high valuation concerns. The company is facing challenges with a net loss of $12.1 million reported for Q2 2026, which reflects ongoing financial difficulties. While the gross margin remains relatively strong at 76.72%, the withdrawal of full-year guidance and a projected EPS loss of $0.42 for the next earnings report suggest caution. The main risk is the high forward P/E ratio, which indicates that the stock may be overvalued given its current financial performance.